Wright G L, Schellhammer P F, Faulconer R J, Reid J W, Brassil D N, Sieg S M
Prostate. 1981;2(2):121-31. doi: 10.1002/pros.2990020202.
The leukocyte migration inhibition (LMI) assay was used to determine the cell-mediated immune reactivity of prostate cancer patients to putative tumor antigens present in potassium chloride extracts of surgically removed prostate tumor tissue. Using an extract prepared from prostate tumor tissue, inhibition of leukocyte migration was found more frequently in prostate tumor patients (61%) than in patients with benign prostate hyperplasia (37%), patients with nonprostate cancers (26%), or normal donors (10%). Control extracts prepared from normal prostate tissue, benign prostate hyperplasia tissue, and unrelated tumor tissue were statistically less reactive in the LMI assay than the prostate tumor extract when reacted against leukocytes from prostate tumor patients. These results suggest that the LMI assay might be potentially useful for measuring the tumor-directed, cell-mediated immune responses in patients with prostate cancer.
采用白细胞迁移抑制（LMI）试验来测定前列腺癌患者对手术切除的前列腺肿瘤组织氯化钾提取物中假定肿瘤抗原的细胞介导免疫反应性。使用从前列腺肿瘤组织制备的提取物，发现前列腺肿瘤患者（61%）中白细胞迁移抑制的发生率高于良性前列腺增生患者（37%）、非前列腺癌患者（26%）或正常供体（10%）。当与前列腺肿瘤患者的白细胞反应时，由正常前列腺组织、良性前列腺增生组织和无关肿瘤组织制备的对照提取物在LMI试验中的反应性在统计学上低于前列腺肿瘤提取物。这些结果表明，LMI试验可能对测量前列腺癌患者的肿瘤定向细胞介导免疫反应具有潜在用途。
